Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Baumann

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
Clinical Pharmacology and Therapeutics|December 13, 2005
Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatmentSéverine Crettol, Jean-Jacques Déglon, Jacques Besson, et al.
Dialogues in Clinical Neuroscience|September 15, 2005
The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressantsPierre Baumann, Sven Ulrich, Gabriel Eckermann, et al.
European Journal of Clinical Pharmacology|April 29, 2004
Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activityChin B Eap, Thierry Buclin, Gianni Cucchia, et al.
Journal of Psychiatric Research|February 24, 2010
Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first-episode schizophrenia treated with quetiapineGeorg Nikisch, Pierre Baumann, Bernhard Kiessling, et al.
Drug Metabolism and Personalized Therapy|December 22, 2017
Creation of the Swiss group of Pharmacogenomics and personalised Therapy (SPT)Ursula Amstutz, Vid Mlakar, Patricia Huezo-Diaz Curtis, et al.
Physiology & Behavior|June 19, 2007
Search for biological correlates of depression and mechanisms of action of antidepressant treatment modalities. Do neuropeptides play a role?Aleksander A Mathé, Henriette Husum, Aram El Khoury, et al.
Plos One|August 31, 2019
Toxicity of locoregional radiotherapy in combination with bevacizumab in patients with non-metastatic breast cancer (TOLERAB): Final long-term evaluationAlice Clément-Zhao, Marie-Laure Tanguy, Paul Cottu, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|May 5, 2009
Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, NiceGuy Goodwin, Wolfgang Fleischhacker, Celso Arango, et al.
General Hospital Psychiatry|May 16, 2003
Major depressive disorder in the general hospital: adaptation of clinical practice guidelinesRachel Voellinger, Alexandre Berney, Pierre Baumann, et al.
Therapeutic Drug Monitoring|November 16, 2020
Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotic DrugsGeorgios Schoretsanitis, Pierre Baumann, Andreas Conca, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
Clinical Pharmacology and Therapeutics|December 13, 2005
Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatmentSéverine Crettol, Jean-Jacques Déglon, Jacques Besson, et al.
Dialogues in Clinical Neuroscience|September 15, 2005
The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressantsPierre Baumann, Sven Ulrich, Gabriel Eckermann, et al.
European Journal of Clinical Pharmacology|April 29, 2004
Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activityChin B Eap, Thierry Buclin, Gianni Cucchia, et al.
Journal of Psychiatric Research|February 24, 2010
Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first-episode schizophrenia treated with quetiapineGeorg Nikisch, Pierre Baumann, Bernhard Kiessling, et al.
Drug Metabolism and Personalized Therapy|December 22, 2017
Creation of the Swiss group of Pharmacogenomics and personalised Therapy (SPT)Ursula Amstutz, Vid Mlakar, Patricia Huezo-Diaz Curtis, et al.
Physiology & Behavior|June 19, 2007
Search for biological correlates of depression and mechanisms of action of antidepressant treatment modalities. Do neuropeptides play a role?Aleksander A Mathé, Henriette Husum, Aram El Khoury, et al.
Plos One|August 31, 2019
Toxicity of locoregional radiotherapy in combination with bevacizumab in patients with non-metastatic breast cancer (TOLERAB): Final long-term evaluationAlice Clément-Zhao, Marie-Laure Tanguy, Paul Cottu, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|May 5, 2009
Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, NiceGuy Goodwin, Wolfgang Fleischhacker, Celso Arango, et al.
General Hospital Psychiatry|May 16, 2003
Major depressive disorder in the general hospital: adaptation of clinical practice guidelinesRachel Voellinger, Alexandre Berney, Pierre Baumann, et al.
Therapeutic Drug Monitoring|November 16, 2020
Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotic DrugsGeorgios Schoretsanitis, Pierre Baumann, Andreas Conca, et al.
Pageof 10